Journals / Bakırköy Tıp Dergisi / 2010 / Cilt: 6 - Sayı: 3

Oral saccharomyces experience in recurrent necrotizing enterocolitis

Tekrarlayan nekrotizan enterokolitte oral saccharomyces

Pages
121–124
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, further studies are needed to confirm the effectiveness of probiotics to treat NEC during neonatal period.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Necrotizing enterocolitis (NEC) is a gastrointestinal disease characterized by intestinal ischemia which is one of the major causes of mortality and morbidity in preterm neonates.
📊
Key Findings & Data:A premature infant with a gestational age of 27 weeks and body weight of 900 gr was diagnosed as sepsis and NEC on postnatal fifth day.
💡
Conclusion & Impact:However, further studies are needed to confirm the effectiveness of probiotics to treat NEC during neonatal period.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Necrotizing enterocolitis (NEC) is a gastrointestinal disease characterized by intestinal ischemia which is one of the major causes of mortality and morbidity in preterm neonates. Recently, probiotics have been used for management of NEC. Lactobacillus species, Bifidobacterium and Saccharomyces boulardii are the most commonly used preparations. We presented a premature infant with recurrent NEC who was treated with Saccharomyces boulardii successfully. A premature infant with a gestational age of 27 weeks and body weight of 900 gr was diagnosed as sepsis and NEC on postnatal fifth day. Physical examination was normal except abdominal distention and there was no peristaltic activity heard by auscultation. In laboratory evaluation, white blood cell count was 30500/mm3, Hb: 16.3 g/dL, platelets: 144000/mm3. Hepatic and renal function tests were within normal limits. Appropriate intravenous (İV) antibiotics and IV hydration were given. On postnatal 10th day, the infant was allowed to be fed by nasogastric tube but this was followed by NEC. After every feeding attempt on postnatal 18, 29, 45 and 64th days, the patient developed NEC; in each episode, he was treated with antibiotics. Oral Saccharomyces boulardii was given to treat recurrent NEC. The premature infant with recurrent NEC was managed successfully by Saccharomyces boulardii as probiotic, a preparation available in Turkey. We did not observe any complications therefore this probiotic might be considered as a safe alternative. However, further studies are needed to confirm the effectiveness of probiotics to treat NEC during neonatal period.

Özet

Nekrotizan enterokolit (NEK), bağırsakların iskemisi ile karakterli bir gastrointestinal sistem hastalığıdır. Preterm yenidoğanlarda morbidite ve mortalitenin önde gelen sebeplerindendir. Son zamanlarda probiyotikler NEK’te tedavi seçeneği olarak denenmektedir. En sık kullanılanları; Lactobacillus türleri, Bifidobacterium ve Saccharomyces boulardii’dir. Burada tekrarlayan NEK’te Saccharomyces boulardii kullanımının faydalı olduğu preterm olgu sunulmuştur. Yirmi yedinci gestasyon haftasında 900 gr olarak dış merkezde doğan bebek, postnatal 5. gününde prematürite-sepsis-NEK ön tanıları ile hastanemize sevkedildi. Muayenesinde abdominal distansiyonu vardı, bağırsak sesleri alınamıyordu. Diğer muayene bulguları doğal idi. Laboratuvarda beyaz küre: 30.500/mm3, Hb: 16,3 gr/dl, plt: 144.000/mm3, biyokimya değerleri normal idi. Hastaya intravenöz sıvı, antibiyotik başlandı. Postnatal 10. günde nazogastrik tüp ile beslendi. Postnatal 18, 29, 45 ve 64. gün hasta oral beslenmeye başlandı ancak NEK gelişti, antibiyotik başlandı. Tekrarlayan NEK tablosu nedeni ile hastaya probiyotik başlanması düşünüldü ve oral Saccharomyces boulardii ampirik olarak başlandı. İzlemde NEK tablosu gelişmedi. Genel durumu düzelen ve oral alımı tolere eden hasta 1800 gr. olarak taburcu edildi. Yenidoğan döneminde tekrarlayan NEK gelişen preterm hastamızda Türkiye’de bulunan S. boulardii probiyotik olarak kullanılmış olup iyi yanıt alınmıştır. Probiyotiğe bağlı komplikasyon gelişmemiş olup güvenilir olduğu düşünülmektedir. Bununla beraber yenidoğan döneminde NEK tedavisinde probiyotiklerle daha ileri çalışmalara ihtiyaç olduğunu düşünmekteyiz.

🔖

Cite This Article

TIRAŞ, Ü., YALAKİ, Z., ÖZTÜRK, A., DALLAR, Y. (2010). Oral saccharomyces experience in recurrent necrotizing enterocolitis. Bakırköy Tıp Dergisi, Cilt: 6 - Sayı: 3, 121–124. https://ajindex.com/articles/130768

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Çetinkaya M, Köksal N. Nekrotizan enterokolit. Güncel Pediatri 2004; 2: 146-151
  2. Embleton ND, Yates R. Probiotics and other preventative strategies for necrotising enterocolitis. Semin Fetal Neonatal Med. 2008; 13: 35-43
  3. Kışlal FM, Dilmen U.Nekrotizan enterokolitis. Türkiye Klinikleri J Ped 2004; 2: 725-729
  4. Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newborns: pathogenesis, prevention and management. Drugs 2008; 68: 1227-1238
  5. Saiman L. Strategies for prevention of nosocomial sepsis in the neonatal intensive care unit. Curr Opin Pediatr 2006; 18: 101-106
  6. Yılmaz M. Prebiyotik ve Probiyotikler. Güncel Pediatri 2004; 2: 142-145
  7. Coşkun T. Pro-, pre-, ve sinbiyotikler. Çocuk Sağlığı ve Hastalıkları Dergisi 2006; 49: 128-148
  8. Barclay AR, Stenson B, Simpson JH, Weaver LT, Wilson DC. Probiotics for necrotizing enterocolitis: a systematic review. J Pediatr Gastroenterol Nutr 2007; 45: 569-576
  9. Kafetzis DA, Skevaki C, Costalos C. Neonatal necrotizing enterocolitis: an overview. Curr Opin Infect Dis 2003; 16: 349-355
  10. Kosloske AM. Epidemiology of necrotizing enterocolitis. Acta Paediatr Suppl 1994; 396: 2-7
  11. Neu J. Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Pediatr Clin North Am 1996; 43: 409-432
  12. Ledbetter DJ, Juul SE. Necrotizing enterocolitis and hematopoietic cytokines. Clin Perinatol 2000; 27: 697-716
  13. Walker WA. Mechanisms of action of probiotics. Clin Infect Dis 2008; 46 Suppl 2: S87-91
  14. Millar M, Wilks M, Costeloe K. Probiotics for preterm infants? Arch Dis Child Fetal Neonatal Ed. 2003; 88: 354-8
  15. Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005; 147: 192-196
  16. Lin HC, Su BH, Chen AC, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005; 115: 1-4
  17. Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 1999; 3: 197-202
  18. Costalos C, Skouteri V, Gounaris A, et al. Enteral feeding of premature infants with Saccharomyces boulardii. Early Hum Dev 2003; 74: 89-96
  19. Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomi